ArticleMolecules (Basel, Switzerland)2026
Antileukemic Activity of
Itzen Aguiñiga-Sánchez, Daniel Romero-Trejo, Karen Miranda-Duarte, Ernesto Romero-López, Jorge Cadena-Iñiguez, Lorena Shira, Juana Rosado-Pérez, Víctor Manuel Mendoza-Núñez, Víctor Manuel Macías Zaragoza, Benny Weiss-Steider and 1 more
Abstract read
In one paragraphArticle in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Itzen Aguiñiga-SánchezHematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, Faculty of High Studies Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.ORCID 0000-0003-1692-8287 Daniel Romero-TrejoHematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, Faculty of High Studies Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.ORCID 0000-0003-3467-0240 Karen Miranda-DuarteHematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, Faculty of High Studies Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.ORCID 0009-0004-8584-8955 Ernesto Romero-LópezResearch Department, Bioplenum Biotechnology Institute, Puerto Vallarta 48313, Mexico.ORCID 0009-0009-5542-0065 Lorena ShiraResearch Department, Bioplenum Biotechnology Institute, Puerto Vallarta 48313, Mexico.
Juana Rosado-PérezResearch Unit on Gerontology, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.ORCID 0000-0002-6147-7502 Víctor Manuel Mendoza-NúñezResearch Unit on Gerontology, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.ORCID 0000-0002-9137-3405 Víctor Manuel Macías ZaragozaDepartment of Biomedical Sciences, School of Medicine, Faculty of High Studies Zaragoza, National Autonomous University of Mexico, Mexico City 56410, Mexico.ORCID 0009-0005-7799-866X Benny Weiss-SteiderHematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, Faculty of High Studies Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.ORCID 0000-0003-4893-530X Edelmiro Santiago-OsorioHematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, Faculty of High Studies Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.ORCID 0000-0002-4876-0688 Funding
General Directorate of Academic Personnel Affairs IA205324National Autonomous University of Mexico IN222023
6 · The paper itselfAbstract
Chronic myeloid leukemia (CML) is driven by constitutive BCR-ABL1 activity and remains clinically challenging due to disease persistence and resistance to tyrosine kinase inhibitors (TKIs). SIRT1, a NAD
Indexed as
Antineoplastic Agents, PhytogenicLeukemia, Myelogenous, Chronic, BCR-ABL PositivePlant ExtractsSirtuin 1Tumor Suppressor Protein p53AcetylationApoptosisCell ProliferationDown-RegulationHumansK562 CellsSignal TransductionAntineoplastic Agents, PhytogenicPlant ExtractsSIRT1 protein, humanSirtuin 1TP53 protein, humanTumor Suppressor Protein p53apoptosischronic myeloid leukemiaimatinibp53 acetylationSechium hybrid H387 extractSIRT1
Identifiers
PMID42738658
PMCPMC13567410
What Socratic holds
Textmetadata
Read underepoch 390